BIOINVEST BREAKING NEWS – Special Update – Anthera (ANTH) – Ending Japanese Deal Is No Big Deal; All B-Mod/Sollpura Programs/Timelines Unchanged – Reiterate BUY – Despite helping financially when ANTH needed the funds last year, no Wall Street models included a Japanese approval for IgAN. The receipt of a termination notice from its development partner in Japan, Zenyaku, was “at will” and alleged no breach of the License Agreement by Anthera. read more…
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.